Brief Report

Ketogenic Diet and microRNAs Linked to Antioxidant Biochemical Homeostasis

Roberto Cannataro 1,†, Maria Cristina Caroleo 2,†, Alessia Fazio 2, Chiara La Torre 2, Pierluigi Plastina 2, Luca Gallelli 3,*, Graziantonio Lauria 2 and Erika Cione 2,*

1 GalaScreen Laboratories, Mater Domini Hospital 88100 Catanzaro and Department of Pharmacy, Health and Nutrition Sciences, University of Calabria, 87036 Rende (CS), Italy
2 Department of Pharmacy, Health and Nutrition Sciences, University of Calabria, Via Pietro Bucci, 87036 Rende (CS), Italy
3 Clinical Pharmacology and Pharmacovigilance Operative Unit, Department of Health Science, University of Magna Graecia, Mater Domini Hospital Catanzaro, 88100 Catanzaro, Italy
* Correspondence: erika.cione@unical.it; Tel.: +39-098-449-3193
† These authors contributed equally to this work.

Received: 30 June 2019; Accepted: 30 July 2019; Published: 2 August 2019

Abstract: Recently, we demonstrated the capability of the ketogenic diet (KD) to influence the microRNA (miR) expression profile. Here, we report that KD is able to normalize miR expression in obese subjects when compared with lean subjects. By applying two different bioinformatics tools, we found that, amongst the miRs returning to comparable levels in lean subjects, four of them are linked to antioxidant biochemical pathways specifically, and the others are linked to both antioxidant and anti-inflammatory biochemical pathways. Of particular interest is the upregulation of hsa-miR-30a-5p, which correlates with the decrease of catalase expression protein in red blood cells.

Keywords: ketogenic diet; microRNAs signature; catalase

1. Introduction

The progress of the obesity pandemic is still substantially underestimated but is alarming [1]. Obese individuals have a lower quality of life and more risk of developing several clinical problems [2]. Obesity is a chronic status with sub-clinical inflammation which is associated with the abnormal synthesis of cytokine/adipokines, leading to an increase of radical oxygen species (ROS) [3]. Therefore, obesity is not per se a disease; rather, it is a status that contributes to the imbalance of anti-inflammatory and oxidative stress biochemical pathways [4]. Opportune antioxidant defenses counteract the action of ROS in different organs and are improved by diverse biomolecules [5–7], functional food and diet nutrients [8,9]. It is worthy of note that, recently, hyperglycemic crisis was linked to oxidative stress in diabetic patients [10]. While ketoacidosis is not safe for human health, it is well known that the ketogenic diet (KD) is safe. KD is a nutritional regimen in which the amount of carbohydrate is maintained at less than 30 g per day [11]. Although its application initially was a therapeutic regimen for refractory epilepsy, today it is often used to lose weight [12]. KD was proved to possess antioxidant and anti-inflammatory properties as well as to regulate obese subjects in stage 1 of the Edmonton Obesity Staging System (EOSS) and their microRNA (miR) expression profile [11,13–15]. The 11 miRNAs analyzed previously in this subject category were normalized with KD when compared to lean subjects. Besides being regulators of the metabolic network in which ROS are always produced, these miRs are also able to counteract inflammatory and oxidative stress [16].

Antioxidants 2019, 8, 269; doi:10.3390/antiox8080269 www.mdpi.com/journal/antioxidants
2. Materials and Methods

2.1. Population

Ethical approval for all human studies was granted in accordance with the Regional Ethics Committee (REC) (#120-18052018). Subjects were also excluded if they showed the presence of hypertension and/or were on medication. The study was considered not to have set up clinical trials and was not registered as such. Written informed consent was obtained from participants which conformed to the standards of ethical practice as outlined in the declaration of Helsinki. The exclusion criteria included diabetes, renal diseases, liver dysfunction, a history of alcohol or drug abuse, and neoplastic diseases in the five years prior to the study.

2.2. Immunoblot Analysis and RNAs Extraction

Blood samples were collected, and red blood cells and lysates for catalase (CAT) expression protein were harvested using the antibody (abcam # ab16731). The protein concentration in samples was estimated as described in [17–20]. Serum plasma was then used for functional genomics assay. Total RNA was extracted from 200 µL of blood serum or plasma by using an miRNeasy Serum/Plasma Kit (Qiagen, Venlo, The Netherlands) in order to lower potential contaminants [15,21] and according to the manufacturer’s instructions.

2.3. NanoString Sample Preparation and Data Analysis

For the n-counter flex of NanoString Technology, 100 ng of RNA/miR was used as input. miRs were then hybridized with an nCounter Human-V3 miRNA Expression Assay CodeSet overnight at 65 °C and as previously described in [22,23]. In order to obtain robust results, the coefficient of variation (CV), expressing the ratio of the standard deviation to the mean and expressed as a percentage, was chosen as 30%. The miRs known to be linked to blood hemolysis were excluded from the analysis [24,25].

2.4. In Silico Prediction of hsa-miR Target Genes

In order to identify genes as targets of hsa-miRs from the array analysis, we performed in silico analysis. The in silico identification of the target genes was performed using miRTargetLink Human (https://cbw-web.cs.uni-saarland.de/mirtargetlink/) and DIANA Tools (http://diana.imis.athena-innovation.gr/DianaTools/index.php) databases. This latter database was used to check which miRNA target genes were already validated experimentally.

2.5. Statistical Analysis

Prism GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, CA, USA) was used to plot the results. Differences within and between groups were evaluated by the t-test and one-way ANOVA followed by a multi-comparison Bonferroni test (* p < 0.05).

3. Results

3.1. Characteristics of Subjects

A total of 43 subjects, divided into categories of obese, lean and on a ketogenic diet (KD), were selected, with numbers for obese subjects of n = 14, lean of n = 17 and KD of n = 12. The subjects’ characteristics are described in Table 1.
Table 1. Subject characteristics.

| Characteristic | Obese (n = 14) | Lean (n = 17) | KD (n = 12) | p Value * |
|----------------|----------------|--------------|-------------|-----------|
| Age, y         | 46.5 ± 10.51   | 46.83 ± 12.32| 46.6 ± 11.56| ns        |
| Height, cm     | 175.1 ± 5.2    | 171.3 ± 6.6  | 176.3 ± 3.3 | ns        |
| Weight, kg     | 107.5 ± 3.0    | 70.8 ± 3.8   | 96.97 ± 11.2| <0.001    |
| BMI, kg/m²     | 33.9 ± 1.2     | 22.1 ± 2.5   | 31.5 ± 1.3  | <0.001    |

Data are presented as mean ± SD. * Using t-test.

3.2. Comparison of Obese, Lean and KD Array Profiles

The heatmap and hierarchical clustering based on the most differentially expressed hsa-miRs are shown in Figure 1, including the signatures of hsa-let-7b-5p, hsa-miR-143-3p, hsa-miR-148b-3p, hsa-miR-26a-5p, hsa-miR-502-5p, hsa-miR-520h, hsa-miR-548d-3p, hsa-miR-590-5p and hsa-miR-644a. In particular, KD, compared to obese subjects, normalized the expression levels of hsa-let-7b-5 (8/12), hsa-miR-143-3p (9/12), hsa-miR-148b-3p (10/12), hsa-miR-590-5p (10/12), hsa-miR-520h (8/12) and hsa-miR-644a (9/12), which were expressed in more than 65% of subjects, while 100% was achieved for hsa-miR-548d-3p (12/12). At least 50% was reached for hsa-miR-26a-5p (6/12), and hsa-miR-502-5p (7/12). No change was seen for hsa-miR-504-5p. The new hsa-miR-let7e-5p (5/12) and hsa-miR-877 (5/12) here identified showed a less than 50% presence, with the exception of hsa-miR-30a-5p (8/12).

![Figure 1](image_url)  
**Figure 1.** Heatmap and hierarchical clustering of obese (n = 14), lean (n = 17) and ketogenic diet (KD) subjects (n = 12) based on the most differentially expressed microRNAs. The color and the intensity of the boxes represent changes of gene expression. In the analysis, red represents down-regulated genes and green represents up-regulated genes. Black represents an unchanged expression as evident by the color reference. n-Solver software was used.

3.3. In Silico Results

Two different databases were used for the in-silico analysis. Data were compared with respect to the number of target genes experimentally validated in both databases. The results are reported in Table 2. Although similar results were found for two hsa-miRs (in bold in Table 2), the numbers of validated targets found for others hsa-miRs were consistently different. In DIANA tools, the numbers of validated target genes were higher in respect to miRtargetLink Human; therefore, DIANA tools were used for further bioinformatics analysis.
Table 2. Bioinformatics tools for in silico analysis.

| Number of Target Genes |
|------------------------|
| miRTargetLink Human    | DIANA Tools |
| hsa-let-7b-5p          | 124         | 312         |
| hsa-let-7e-5p          | 15          | 273         |
| hsa-miR-143-3p         | 32          | 82          |
| hsa-miR-148b-3p        | 10          | 218         |
| hsa-miR-26a-5p         | 52          | 391         |
| hsa-miR-30a-5p         | 119         | 458         |
| hsa-miR-30e-5p         | 7           | 412         |
| hsa-miR-502-5p         | 3           | 30          |
| hsa-miR-504-5p         | 6           | 7           |
| hsa-miR-520h           | 5           | 5           |
| hsa-miR-548d-3p        | 1           | 203         |
| hsa-miR-590-5p         | 2           | 43          |
| hsa-miR-644a           | 2           | 0           |
| hsa-miR-877            | 0           | 19          |

3.4. Validated hsa-miR Interaction and Western Blot Analysis of Catalase

Predicted and validated target genes were assessed using DIANA Tools. The new hsa-miR-let7e-5p was found to regulate glutathione peroxidase 7 (GPX7), as shown by string analysis (Figure 2A), as well as in silico 3’UTR interaction (Figure 2B). In silico 3’UTR regions of tet methylcytosine dioxygenase 3 (TET3) for hsa-miR-520h (Figure 2D) interaction and 3’UTR regions of superoxide dismutase 2 (SOD2) for hsa-miR-548d-3p (Figure 2F) are shown, as well as string analysis, in Figure 2C,E, respectively.

Table 3. Antioxidant metabolism and inflammatory-related genes.

| Biochemical Pathways and Possible miRs Gene Interaction |
|--------------------------------------------------------|
| miRNA                                | Validated target genes                        |
| Glutathione metabolism               | GPX7, GSR, RRM2, GGCT                          |
|                                       | GPX7                                            |
|                                       | RRM2                                            |
|                                       | CHPF2, XYLT2                                    |
| Chondroitin sulfate biosynthesis      | CYP2J2, GPX7, LTA4H, PTGS1, PTGS2, PTGES2       |
| Arachidonic acid metabolism           | PTGS1, PTGS2                                   |
Table 3. Cont..

| Biochemical Pathways and Possible miRs Gene Interaction |
|---------------------------------------------------------|
| **Toll like receptor signalling pathway**               |
| hsa-let-7b-5p                                          | IFNB1, NFKBIA, MAPK1, MAP2K2, TAB2 |
| hsa-miR-26a-5p                                          | IFNB1, IL6 |
| hsa-miR-30e-5p                                          | CAT |
| hsa-miR-877-5p                                          | MAPK8 |
| hsa-miR-148b-3p                                         | PIK3CA, PIK3CG |
| hsa-miR-143-3p                                          | AKT1 |
| hsa-miR-520h                                           | TET3 |
| **Natural killer cell mediated cytotoxicity and T Cell, B Cell receptor signalling pathways** |
| hsa-let-7b-5p                                          | IFNB1, NFATC1, NFATC3, NRAS, NFKBIA, PAK1, MAPK1, MAP2K2, PDK1, CD81 |
| hsa-miR-26a-5p                                          | IFNB1, SHC2, IL6 |
| hsa-miR-30e-5p                                          | RELA, CAT |
| hsa-miR-504-5p                                          | FAS |
| hsa-miR-877-5p                                          | NFAT5, NRAS, PIK3CCA |
| hsa-miR-143-3p                                          | HRAS, Kras, AKT1 |
| hsa-miR-148a-3p                                         | HLA-G, CCL28 |
| hsa-miR-548d-3p                                         | AKT3, SOD2 |

Table 4. Abbreviations and gene names.

| Abbreviation | Gene Name                                      |
|--------------|-----------------------------------------------|
| AKT1         | Serine-threonine protein kinase 1             |
| AKT3         | Serine-threonine protein kinase 3             |
| CAT          | Catalase                                       |
| CCL28        | C-C motif chemokine 28 precursor              |
| CD81         | CD81 antigen target proliferate antibody 1    |
| CHP12        | Chondroitin polymerizing factor 2              |
| CYP2J2       | Cytochrome P450 2J2                           |
| FAS          | FAS cell surface death receptor                |
| GGT7         | Gamma-glutamylcyclotransferase                |
| GPX7         | Glutathione peroxidase 7                      |
| GSR          | Glutathione disulphide reductase              |
| HLA-G        | HLA Class I Histocompatibility Antigen, Alpha Chain G |
| HRAS         | Hras protooncogene GTPase                     |
| IFNB1        | Interferon beta 1                             |
| IL6          | Interleukin-6                                 |
| KRAS         | Kras protooncogene GTPase                     |
| LTA4H        | Leukotriene-A4 hydrolase                     |
| MAP2K2       | Mitogen-activated protein kinase 2            |
| MAPK1        | Mitogen-activated protein kinase 1            |
| MAPK8        | Mitogen-activated protein kinase 8            |
| NFAT5        | Nuclear factor of activated T-cells 5         |
| NFATC1       | Nuclear factor of activated T cells 1         |
| NFATC3       | Nuclear factor of activated T cells 3         |
| NFKBIA       | NFKB inhibitor alpha                          |
| NRAS         | NRAS proto-oncogene                           |
| PAK1         | Serine/threonine-protein kinase               |
| PDK1         | Phosphoinositide-dependent kinase-1           |
| PIK3CA       | Phosphoinositide-3-kinase                     |
| PIK3CG       | Phosphoinositide-4,5-Bisphosphatase 3-kinase  |
| PTGES2       | Prostaglandin-E synthase 2                    |
| PTGS1        | Prostaglandin-endoperoxidase synthase 1       |
| PTGS2        | Prostaglandin-endoperoxidase synthase 2       |
| PTE2         | Prostaglandin-E synthase 2                    |
| RELA         | RELA proto-oncogene                           |
| RRM2         | Ribonucleotide reductase regulatory subunit M2|
| SHC2         | SHC transforming protein 2                    |
| TAB2         | TGF-beta activated kinase 1 binding protein 2 |
| XYLIT2       | Xylosyltransferase 2                          |
Figure 2. Bioinformatics analysis. String protein interaction of (A) GPX7 and (B) GPX7 in silico interactions with the 3′UTR region. String protein interaction of (C) TET3 and its in silico interactions with the 3′UTR region in (D). String protein interaction of (E) SOD2 and its in silico interactions with the 3′UTR region in (F).

Figure 3. A ketogenic diet (KD) influences catalase gene expression. (A) Western blot analysis of catalase (CAT) protein levels in red blood cells from obese, lean and subject in KD. (B) Graphical representation of Western blot band intensity, normalized with the loading control GAPDH. (C) The CAT gene 3′UTR region interacts with hsa-miR-30a-5p. (D) The protein network of CAT enzymes determined by string analysis. Data in panel B represent means ± SD of n = 2 for obese, n = 3 for lean and n = 2 for KD independent tests (* p < 0.05).
4. Discussion

The World Health Organization states that obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults were overweight. Of these, over 650 million were obese, leading to the following report sentence: “Most of the world’s population live in countries where overweight and obesity kills more people than underweight. Obesity is preventable” [26]. How can obesity be preventable? One method is represented by KD. The beneficial effects of KD in reducing the body weight and body mass index of obese subjects over both the short (6 weeks) and long (24 weeks) term has already been proven [12,27]. The administration of KD for a relatively long period is safe and can be considerate a nutritional therapy for weight reduction in obese patients [27]. Besides that, to keep KD beneficial, lifestyle change is mandatory and is the harder part of nutritional intervention during KD, with documented improvement of the endurance exercise capacity, better recovery from fatigue and exercise-induced muscle and organ damage prevention in obese subjects. Besides that, the anti-inflammatory action of physical activity was also recently reviewed [28,29]. Nutraceuticals with antioxidant properties were proposed to help in the treatment of obesity, but they are not enough when taken alone [30]. Several scientific approaches to date have tried to describe this disorder by way of genetic or environmental factors [31]. The role of epigenetics in human diseases has been well described relatively recently. Obesity and epigenetics is a consolidated union [32–34], and bariatric surgery induces epigenetic change in obese subjects [35]. We recently reported the influence of the ketogenic diet (KD) on the circulating microRNA (miR) expression profile [15]. The 11 miRs controlling the metabolic network identified so far in subjects on KD were almost normalized and closer to lean subjects. Besides that, new miRs targeting identified genes linked to the homeostasis of oxidant–antioxidant pathways were identified. These latter molecules act as epigenetic regulators and have the peculiarity of regulating gene expression targeting the 3′UTR mRNA region [31]. Predicted and validated target genes were assessed using DIANA Tools. The hsa-miR-let7e-5p has a role in pathogen recognition [36]. A low level of hsa-miR-520h was found in the alteration of the placenta, mediated by oxidative stress [37], and hsa-miR-548d-3p was found to be involved in the control of the homeostasis of oxidative stress damage, the metabolic network and survival pathways [38]. Here, we found an in silico interaction of that miR with glutathione peroxidase 7 (GPX7), tet methylcytosine dioxygenase 3 (TET3) and superoxide dismutase 2 (SOD2). GPX7 is a glutathione peroxidase homolog for which the exact biochemistry is not fully understood [39]. TET3, which is aberrantly expressed in acute myeloid leukemia, promotes DNA oxidation [40,41]. The mitochondria-localized manganese superoxide, SOD2, has a dichotomous role and aids in the regulation of several types of cancers [42]. All those proteins directly or indirectly exhibit a physical interaction with CAT. This latter protein was monitored through Western blot analysis and decreased after KD regime. The hsa-miR-30a-5p was found to target the 3′UTR regions of CAT. It is worth noting that the family of hsa-miR-30, to which hsa-miR-30a-5p belongs, is a promising regulator in both development and disease [41]. In the interplay of oxidative stress, pro-oxidants, and antioxidants, this is already known [43]. In particular, the regulation of antioxidant genes such as SOD, CAT, and GPX was studied in mice models kept in KD. The short time-frame of KD did not affect the SOD expression protein while it significantly decreased both GPX and CAT [44].

5. Conclusions

Modulating miRs linked to antioxidant and inflammatory states in obese people might be the key to the success, in particular in the long term, of a nutritional program. The reciprocal action of diet and nutrients on anti-oxidant and anti-inflammatory miRs can present tools to predict and follow the success of a nutritional programs.

Author Contributions: R.C. and E.C. designed the study and the experiments; M.C.C., C.L.T. and E.C. carried out the experiments; E.C., A.F. and M.C.C. analysed the data and revised the statistical analyses; P.P., G.L. and L.G. facilitated the experiments; E.C. prepared and edited the manuscript; and all authors approved it.

Funding: This research received no external funding.
**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Sorensen, T.I.; Virtue, S.; Vidal-Puig, A. Obesity as a clinical and public health problem: Is there a need for a new definition based on lipotoxicity effects? *Biochim. Biophys. Acta* **2010**, *1801*, 400–404. [CrossRef] [PubMed]

2. Ezzati, M.; Bentham, J.; Di Cesare, M.; Bilano, V.; Bixby, H.; Zhou, B.; Stevens, A.G.; Riley, M.L.; Taddei, C.; Hajifathalian, K.; et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *Lancet* **2017**, *380*, 2627–2642.

3. Li, J.; Shen, X. Oxidative stress and adipokine levels were significantly correlated in diabetic patients with hyperglycemic crises. *Diabetol. Metab. Syndr.* **2019**, *11*, 13. [CrossRef] [PubMed]

4. Fernández-Sánchez, A.; Madrigal-Santillán, E.; Bautista, M.; Esquivel-Soto, J.; Morales-Gonzalez, A.; Esquivel-Chirino, C.; Durante-Montiel, I.; Sánchez-Rivera, G.; Valadez-Vega, C.; Morales-Gonzalez, J.A. Inflammation, oxidative stress, and obesity. *Int. J. Mol. Sci.* **2011**, *12*, 3117–3132. [CrossRef] [PubMed]

5. Franco, R.; Navarro, G.; Martínez-Pinilla, E. Antioxidant Defense Mechanisms in Erythrocytes and in the Central Nervous System. *Antioxidants (Basel)* **2019**, *8*, 46. [CrossRef] [PubMed]

6. Tucci, P.; Cione, E.; Perri, M.; Genchi, G. All-trans-retinoic acid induces apoptosis in Leydig cells via activation of the mitochondrial death pathway and antioxidant enzyme regulation. *J. Bioenerg. Biomembr.* **2008**, *40*, 315–323. [CrossRef] [PubMed]

7. Lobo, V.; Patil, A.; Phatak, A.; Chandra, N. Free radicals, antioxidants and functional foods: Impact on human health. *Pharmacogn. Rev.* **2010**, *4*, 118–126. [CrossRef] [PubMed]

8. Spalice, A.; Guido, C.A. Cardiovascular Risks of Ketogenic Diet for Glut-1 Deficiency. *Pediatr. Neurol. Briefs* **2018**, *3*, 8. [CrossRef]

9. Iacovides, S.; Meiring, R.M. The effect of a ketogenic diet versus a high-carbohydrate, low-fat diet on sleep, cognition, thyroid function, and cardiovascular health independent of weight loss: Study protocol for a randomized controlled trial. *Trials* **2018**, *19*, 62. [CrossRef]

10. Pinto, A.; Bonucci, A.; Maggi, E.; Corsi, M.; Businaro, R. Anti-Oxidant and Anti-Inflammatory Activity of Ketogenic Diet: New Perspectives for Neuroprotection in Alzheimer’s Disease. *Antioxidants (Basel)* **2018**, *7*, 63. [CrossRef]

11. Canning, K.L.; Brown, R.E.; Wharton, S.; Sharma, A.M.; Kuk, J.L. Edmonton Obesity Staging System Prevalence and Association with Weight Loss in a Publicly Funded Referral-Based Obesity Clinic. *J. Obes.* **2015**, *2015*, 619734. [CrossRef] [PubMed]

12. Cannataro, R.; Perri, M.; Gallelli, L.; Caroleo, M.C.; De Sarro, G.; Cione, E. Ketogenic Diet Acts on Body Remodeling and MicroRNAs Expression Profile. *Microrna* **2019**, *8*, 116–126. [CrossRef] [PubMed]

13. Tan, B.L.; Norhaizan, M.E.; Liew, W.P. Nutrients and Oxidative Stress: Friend or Foe? *Oxid. Med. Cell. Longev.* **2018**, *2018*, 9719584. [CrossRef] [PubMed]

14. Malivindi, R.; Raú, V.; De Rose, D.; Gervasi, M.C.; Cione, E.; Russo, G.; Santoro, M.; Aquila, S. Influence of all-trans retinoic acid on sperm metabolism and oxidative stress: Its involvement in the physiopathology of varicocele-associated male infertility. *J. Cell. Physiol.* **2018**, *233*, 9526–9537. [CrossRef] [PubMed]

15. Perri, M.; Pingitore, A.; Cione, E.; Vilardi, E.; Perrone, V.; Genchi, G. Proliferative and anti-proliferative effects of retinoic acid at doses similar to endogenous levels in Leydig MLTC-1/R2C/TM-3 cells. *Biochim. Biophys. Acta* **2010**, *1800*, 993–1001. [CrossRef] [PubMed]

16. Cione, E.; Pingitore, A.; Perri, M.; Genchi, G. Influence of all-trans-retinoic acid on oxoglutarate carrier via retinoylation reaction. *Biochim. Biophys. Acta* **2009**, *1791*, 3–7. [CrossRef] [PubMed]

17. Mohanty, J.G.; Shukla, H.D.; Williamson, J.D.; Launer, L.J.; Saxena, S.; Rifkind, J.M. Alterations in the red blood cell membrane proteome in alzheimer’s subjects reflect disease-related changes and provide insight into altered cell morphology. *Proteome Sci.* **2010**, *8*, 11. [CrossRef]

18. Gallelli, L.; Falcone, D.; Pelaia, G.; Renda, T.; Terracciano, R.; Malara, N.; Vatrella, A.; Sanduzzi, A.; D’Agostino, B.; Rossi, F.; et al. Interleukin-6 receptor superantagonist Sant7 inhibits TGF-beta-induced proliferation of human lung fibroblasts. *Cell Prolif.* **2008**, *41*, 393–407. [CrossRef]
19. Pelaia, G.; Gallelli, L.; D’Agostino, B.; Vatrella, A.; Cuda, G.; Fratto, D.; Renda, T.; Galderisi, U.; Piegari, E.; Crimi, N.; et al. Effects of TGF-beta and glucocorticoids on map kinase phosphorylation, IL-6/IL-11 secretion and cell proliferation in primary cultures of human lung fibroblasts. *J. Cell. Physiol.* 2007, 210, 489–497. [CrossRef]

20. Perri, M.; Lucente, M.; Cannataro, R.; De Luca, I.F.; Gallelli, L.; Moro, G.; De Sarro, G.; Caroleo, M.C.; Cione, E. Variation in Immune-Related microRNAs Profile in Human Milk Amongst Lactating Women. *MicroRNA* 2018, 7, 107–114. [CrossRef]

21. Geiss, G.K.; Bumgarner, E.R.; Birditt, B.; Dahl, T.; Dowidar, N.; Dunaway, D.L.; Fell, H.P.; Ferree, S.; George, R.D.; Grogan, T.; et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. *Nat. Biotechnol.* 2012, 30, 317–325. [CrossRef] [PubMed]

22. Foye, C.; Yan, I.K.; David, W.; Shukla, N.; Habboush, Y.; Chase, L.; Ryland, K.; Kesari, V.; Patel, T. Comparison of miRNA quantitation by Nanostring in serum and plasma samples. *PLoS ONE* 2017, 12, e0189165. [CrossRef] [PubMed]

23. Wagott, D.; Chu, K.; Yin, S.; Wouters, B.G.; Liu, F.-F.; Boutros, P.C. NanoStringNorm: An extensible R package for the pre-processing of NanoString mRNA and miRNA data. *Bioinformatics* 2012, 28, 1546–1548. [CrossRef] [PubMed]

24. Shkurnikov, M.Y.; Knyazev, E.N.; Mikhailenko, D.S.; Nyushko, K.M.; Saribekyan, E.K.; Samatov, T.R.; Alekseev, B.Y.; Knyazev, E. Analysis of Plasma microRNA Associated with Hemolysis. *Bull. Exp. Biol. Med.* 2016, 160, 748–750. [CrossRef] [PubMed]

25. Abdali, D.; Samson, S.E.; Grover, A.K. How effective are antioxidant supplements in obesity and diabetes? *Med. Princ. Pract.* 2015, 24, 201–215. [CrossRef] [PubMed]

26. Burgio, E.; Lopomo, A.; Migliore, L. Obesity and diabetes: From genetics to epigenetics. *Mol. Biol. Rep.* 2015, 42, 799–818. [CrossRef] [PubMed]

27. Dashti, H.M.; Mathew, T.C.; Hussein, T.; Asfar, S.K.; Behbahani, A.; Khoursheed, M.; Al-Sayer, H.M.; Bo-Abbas, Y.Y.; Al-Zaid, N.S. Long-term effects of a ketogenic diet in obese patients. *Exp. Clin. Cardiol.* 2004, 9, 200–205. PMCID: PMC2716748. [PubMed]

28. Ma, S.; Suzuki, K. Keto-Adaptation and Endurance Exercise Capacity, Fatigue Recovery, and Exercise-Induced Muscle and Organ Damage Prevention: A Narrative Review. *Sports (Basel)* 2019, 7, 40. PMCID: PMC6410243. [CrossRef] [PubMed]

29. Suzuki, K. Chronic Inflammation as an Immunological Abnormality and Effectiveness of Exercise. *Biomolecules* 2019, 9, 223. [CrossRef]

30. Ling, C.; Ronn, T. Epigenetics in Human Obesity and Type 2 Diabetes. *Cell Metab.* 2019, 29, 1028–1044. [CrossRef]

31. Herrera, B.M.; Lindgren, C.M. The genetics of obesity. *Curr. Diabetes Rep.* 2010, 10, 498–505. [CrossRef]

32. Lopomo, A.; Burgio, E.; Migliore, L. Epigenetics of Obesity. *Prog. Mol. Biol. Transl. Sci.* 2016, 140, 151–184. [CrossRef]

33. Izquierdo, A.G.; Crujeiras, A.B. Obesity-Related Epigenetic Changes After Bariatric Surgery. *Front. Endocrinol.* 2019, 10, 232. [CrossRef]

34. Sato, F.; Tsuchiya, S.; Meltzer, S.J.; Shimizu, K. MicroRNAs and epigenetics. *FEBS J.* 2011, 278, 1598–1609. [CrossRef]

35. Hildebrand, D.; Eberle, M.E.; Wölfl, S.M.; Egler, F.; Sahin, D.; Sahr, A.; Bode, K.A.; Heeg, K. Hsa-miR-99b/let-7e/miR-125a Cluster Regulates Pathogen Recognition Receptor-Stimulated Suppressive Antigen-Presenting Cells. *Front. Immunol.* 2018, 9, 1224. [CrossRef]

36. Rudov, A.; Balduini, W.; Carloni, S.; Perrone, S.; Buonocore, G.; Albertini, M.C. Involvement of miRNAs in placental alterations mediated by oxidative stress. *Oxid. Med. Cell. Longev.* 2014, 2014, 103068. [CrossRef]

37. Engedal, N.; Žerovnik, E.; Rudov, A.; Galli, F.; Olivieri, F.; Procopio, A.D.; Rippo, M.R.; Monsurro, V.; Betti, M.; Albertini, M.C. From Oxidative Stress Damage to Pathways, Networks, and Autophagy via MicroRNAs. *Oxid. Med. Cell. Longev.* 2018, 2018, 4968321. [CrossRef]

38. Maiorino, M.; Bosello-Travain, V.; Cozza, G.; Miotto, G.; Roveri, A.; Toppo, S.; Zaccarin, M.; Urisini, F. Understanding mammalian glutathione peroxidase 7 in the light of its homologs. *Free Radic. Biol. Med.* 2015, 83, 352–360. [CrossRef]

39. Peng, J.; Yang, Q.; Li, A.-F.; Li, R.-Q.; Wang, Z.; Liu, L.-S.; Ren, Z.; Zheng, X.-L.; Tang, X.-Q.; Li, G.-H.; et al. Tet methylcytosine dioxygenase 2 inhibits atherosclerosis via upregulation of autophagy in ApoE-/- mice. *Oncotarget* 2016, 7, 76423–76436. [CrossRef]
40. Kurian, J.R.; Louis, S.; Keen, K.L.; Wolfe, A.; Terasawa, E.; Levine, J.E. The Methylcytosine Dioxygenase Ten-Eleven Translocase-2 (tet2) Enables Elevated GnRH Gene Expression and Maintenance of Male Reproductive Function. *Endocrinology* 2016, 157, 3588–3603. [CrossRef]

41. Mao, L.; Liu, S.; Hu, L.; Jia, L.; Wang, H.; Guo, M.; Chen, C.; Liu, Y.; Xu, L. miR-30 Family: A Promising Regulator in Development and Disease. *BioMed Res. Int.* 2018, 2018, 9623412. [CrossRef]

42. Kim, Y.S.; Vallur, P.G.; Phaëton, R.; Mythreye, K.; Hempel, N. Insights into the Dichotomous Regulation of SOD2 in Cancer. *Antioxidants (Basel)* 2017, 6, 86. [CrossRef]

43. Rahal, A.; Kumar, A.; Singh, V.; Yadav, B.; Tiwari, R.; Chakraborthy, S.; Dhama, K. Oxidative stress, prooxidants, and antioxidants: The interplay. *BioMed Res. Int.* 2014, 2014, 761264. [CrossRef]

44. Kephart, W.C.; Mumford, P.W.; Mao, X.; Romero, M.A.; Hyatt, H.W.; Zhang, Y.; Mobley, C.B.; Quindry, J.C.; Young, K.C.; Beck, D.T.; et al. The 1-Week and 8-Month Effects of a Ketogenic Diet or Ketone Salt Supplementation on Multi-Organ Markers of Oxidative Stress and Mitochondrial Function in Rats. *Nutrients* 2017, 9, 1019. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).